Compare Clorox Co (CLX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Clorox Co vs Regeneron Pharmaceuticals Inc — how do they compare? Clorox Co trades at $108.39 (market cap $13.02B), while Regeneron Pharmaceuticals Inc trades at $793.6 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.4× Clorox Co's market cap, and Clorox Co pays the higher dividend (4.64%). Which is the better fit depends on your goals.
| CLX | REGN | |
|---|---|---|
Market Cap | $13.02B | $83.19B |
Sector | Consumer Staples | Health |
52-Week High | $127.16 | $812.27 |
52-Week Low | $86.12 | $545.94 |
Enterprise Value | $18.40B | $77.90B |
Dividend Yield | 4.64% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Clorox (CLX) trades at $105.15, down 0.43% today, with a bullish technical signal from moving averages and strong momentum indicators. Recent Q2 2026 earnings beat expectations with EPS of $1.66, though Q4 2025 missed. The company reported fiscal 2025 revenue of $7.10 billion and net income of $810 million, with a high ROE of 285.64% but elevated P/B ratio of 141.28. Dividend increased to $1.25 per share, payable August 28, 2026.
Outlook is mixed: bullish technicals and profitability contrast with analyst caution (10.34% buy ratings) and a consensus price target of $97.50 below current price. Risks include inflation pressures and competitive threats from private labels. Upside hinges on execution of cost-saving initiatives and market share recovery.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
